Allergy and Respiratory Diseases Clinic, DIMI, University of Genoa, IRCCS AOU San Martino-IST, Genova, Italy.
Respir Med. 2013 Mar;107(3):361-7. doi: 10.1016/j.rmed.2012.11.004. Epub 2012 Dec 4.
Assessing patient's perspective provides useful information enabling a customized approach which has been advocated by current guidelines. In this multicentre cross-sectional study we evaluated personal viewpoints on allergen-specific immunotherapy (SIT) in patients treated with subcutaneous (SCIT) or sublingual (SLIT) immunotherapy.
A survey of 28 questions assessing patient's knowledge, perceptions, expectations and satisfaction was developed by an expert panel and was applied by physicians from allergology centres in patients with respiratory allergy treated with SIT. Treating physicians independently reported their satisfaction level regarding SIT for each patient.
Fully completed surveys from 434 patients (55.3% male; 66.7% poly-sensitized, 74% SLIT) were analysed. Mean duration of SIT was 2.5 years with different allergens. Most patients acquired their SIT knowledge from their physician (95%) and consequently, their physicians' opinion in their choice to start with SIT was important. Most patients perceived SIT to be safe and easy to integrate into their daily routine. The main motivations for SIT were its supposed potential to alter the course of the disease (45.7%), less need of (28.2%), or dissatisfaction with current pharmacotherapy (19.3%). Both patients' and physicians' satisfaction was high (VAS-scores 74/100 and 78/100, respectively) and showed a significant correlation (SCIT: r=0.612; SLIT: r=0.608). No major difference was found in patients' answers based on the level of education.
In this real life study evaluating different aspects of patient's perspective on SIT, the majority of patients had an adequate level of knowledge, perceptions, expectations and satisfaction about SIT, which corresponded well with the physician's perceptions and satisfaction. Our data warrant the use of patient's perspectives on chronic SIT treatment.
评估患者的观点提供了有用的信息，使个性化的方法成为可能，这符合当前指南的建议。在这项多中心横断面研究中，我们评估了接受皮下（SCIT）或舌下（SLIT）免疫治疗的患者对过敏原特异性免疫治疗（SIT）的个人观点。
一个由专家小组制定的包含 28 个问题的调查评估了患者的知识、看法、期望和满意度，由过敏中心的医生在接受 SIT 治疗的呼吸道过敏患者中应用。治疗医生独立报告了他们对每位患者 SIT 的满意度水平。
对 434 名患者（55.3%为男性；66.7%多敏化，74%为 SLIT）的完整调查问卷进行了分析。SIT 的平均持续时间为 2.5 年，使用了不同的过敏原。大多数患者从医生那里获得 SIT 知识（95%），因此，他们的医生在开始 SIT 时的意见很重要。大多数患者认为 SIT 安全且易于融入日常生活。接受 SIT 的主要动机是其改变疾病进程的潜在可能性（45.7%）、减少（28.2%）或对当前药物治疗的不满（19.3%）。患者和医生的满意度都很高（VAS 评分分别为 74/100 和 78/100），并且呈显著相关性（SCIT：r=0.612；SLIT：r=0.608）。根据教育程度的不同，患者的回答没有明显差异。
在这项评估患者对 SIT 不同观点的真实生活研究中，大多数患者对 SIT 的知识、看法、期望和满意度处于适当水平，这与医生的看法和满意度相符。我们的数据证明了使用患者对慢性 SIT 治疗的观点是合理的。
